Index -
P/E -
EPS (ttm) -12.68
Insider Own 0.00%
Shs Outstand 2.52M
Perf Week -19.22%
Market Cap 7.84M
Forward P/E -
EPS next Y -5.11
Insider Trans -
Shs Float 2.52M
Perf Month -60.88%
Income -21.24M
PEG -
EPS next Q -2.26
Inst Own 14.06%
Short Float 3.44%
Perf Quarter -37.68%
Sales 0.00M
P/S -
EPS this Y 54.77%
Inst Trans 11.89%
Short Ratio 2.86
Perf Half Y -62.84%
Book/sh 4.04
P/B 0.77
EPS next Y 4.66%
ROA -117.54%
Short Interest 0.09M
Perf Year -80.50%
Cash/sh 2.17
P/C 1.43
EPS next 5Y -
ROE -130.94%
52W Range 3.00 - 21.25
Perf YTD -55.70%
Dividend Est. -
P/FCF -
EPS past 5Y -13.86%
ROI -221.31%
52W High -85.36%
Beta 1.42
Dividend TTM -
Quick Ratio 3.13
Sales past 5Y 0.00%
Gross Margin -
52W Low 3.67%
ATR (14) 0.68
Dividend Ex-Date -
Current Ratio 3.13
EPS Y/Y TTM 56.46%
Oper. Margin 0.00%
RSI (14) 26.23
Volatility 10.69% 13.93%
Employees 19
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 24.50
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q 60.48%
Payout -
Rel Volume 0.12
Prev Close 3.13
Sales Surprise 14.30%
EPS Surprise 5.19%
Sales Q/Q -
Earnings Mar 28 AMC
Avg Volume 30.26K
Price 3.11
SMA20 -38.93%
SMA50 -51.03%
SMA200 -59.24%
Trades
Volume 3,671
Change -0.80%
Date
Action
Analyst
Rating Change
Price Target Change
May-19-22 Resumed
H.C. Wainwright
Buy
$22
Feb-08-21 Initiated
H.C. Wainwright
Buy
$31
Dec-07-20 Initiated
B. Riley Securities
Buy
$36
Aug-17-20 Reiterated
Maxim Group
Buy
$12 → $18
Jul-08-20 Initiated
Maxim Group
Buy
$12
Apr-15-24 07:00AM
Mar-28-24 10:54PM
04:05PM
Mar-27-24 04:01PM
Mar-25-24 09:01AM
03:11PM
Loading…
Mar-22-24 03:11PM
Mar-20-24 12:00PM
09:03AM
Mar-14-24 04:47PM
Jan-24-24 08:00AM
Jan-09-24 08:00AM
Dec-20-23 10:52AM
10:52AM
Dec-19-23 06:00AM
Dec-18-23 04:01PM
07:00AM
Loading…
Dec-15-23 07:00AM
Dec-13-23 08:00AM
Nov-30-23 08:00AM
08:00AM
Nov-27-23 07:00AM
Nov-16-23 08:37AM
Nov-14-23 04:05PM
Nov-08-23 04:05PM
Nov-07-23 04:05PM
Oct-02-23 05:00PM
Sep-28-23 04:29PM
Aug-23-23 07:00AM
Aug-17-23 04:01PM
06:36AM
Aug-16-23 04:25AM
(Thomson Reuters StreetEvents) -9.76%
06:05AM
Loading…
Aug-15-23 06:05AM
06:00AM
Aug-14-23 04:01PM
Aug-09-23 08:30AM
Aug-08-23 05:50PM
Jul-31-23 07:00AM
Jun-26-23 07:00AM
May-23-23 04:05PM
May-11-23 04:05PM
May-09-23 07:15AM
May-04-23 08:00AM
May-01-23 07:00AM
Apr-08-23 08:58AM
Mar-07-23 04:15PM
Mar-06-23 04:05PM
Feb-23-23 01:01PM
Feb-08-23 04:05PM
Jan-09-23 08:00AM
Dec-05-22 06:30AM
Nov-29-22 04:01PM
Nov-21-22 01:40PM
Nov-18-22 08:00AM
Nov-17-22 04:01PM
05:34AM
Nov-14-22 04:01PM
Nov-07-22 04:05PM
Nov-03-22 08:00AM
Nov-02-22 12:47PM
Nov-01-22 04:07PM
04:05PM
Oct-18-22 10:23AM
Oct-11-22 08:00AM
Sep-26-22 08:00AM
Sep-22-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Aug-12-22 11:30AM
Aug-11-22 04:05PM
Aug-02-22 04:05PM
Jul-14-22 08:00AM
Jun-24-22 03:44PM
Jun-09-22 08:00AM
Jun-01-22 08:00AM
May-31-22 09:55AM
May-20-22 09:32AM
May-11-22 05:15PM
04:01PM
May-10-22 03:34PM
May-02-22 08:00AM
Apr-29-22 07:30AM
Apr-28-22 08:04AM
Apr-19-22 08:00AM
Apr-05-22 09:09PM
Mar-25-22 12:00AM
Mar-24-22 05:45PM
04:26PM
Mar-17-22 11:07AM
08:00AM
Mar-11-22 07:05AM
Mar-09-22 04:05PM
Mar-07-22 10:16AM
Mar-01-22 08:00AM
Feb-24-22 02:29PM
09:27AM
Jan-27-22 08:00AM
Jan-12-22 09:34AM
Dec-21-21 08:00AM
Dec-06-21 08:00AM
Nov-16-21 01:00AM
Nov-15-21 05:25PM
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
CARLSON CAPITAL L P 10% Owner Aug 16 '23 Sale 0.39 1,000 392 5,064,000 Aug 17 05:29 PM Weisman Harlan F President and CEO Aug 15 '23 Buy 0.25 600,000 150,000 814,615 Aug 15 08:00 AM Mikhak Zamaneh Chief Medical Officer Aug 15 '23 Buy 0.25 120,000 30,000 135,000 Aug 15 08:00 AM MILLS ROBERT S Director Aug 15 '23 Buy 0.25 40,000 10,000 55,980 Aug 15 08:00 AM COLEMAN KIRK ALLEN Chief Financial Officer Aug 15 '23 Buy 0.25 20,000 5,000 35,675 Aug 15 08:00 AM Roberts Brandi Director Aug 15 '23 Buy 0.25 20,000 5,000 20,000 Aug 15 08:00 AM ROCAMBOLI STEPHEN Director Aug 15 '23 Buy 0.25 20,000 5,000 36,000 Aug 15 08:00 AM CARLSON CAPITAL L P 10% Owner Aug 15 '23 Sale 0.44 215,000 94,041 5,065,000 Aug 17 05:29 PM
Index -
P/E -
EPS (ttm) -0.86
Insider Own 22.70%
Shs Outstand 32.17M
Perf Week -6.12%
Market Cap 71.76M
Forward P/E -
EPS next Y -1.20
Insider Trans 0.06%
Shs Float 30.15M
Perf Month -6.60%
Income -25.79M
PEG -
EPS next Q -0.25
Inst Own 17.04%
Short Float 0.50%
Perf Quarter -20.00%
Sales 0.00M
P/S -
EPS this Y -13.40%
Inst Trans -0.79%
Short Ratio 0.73
Perf Half Y 41.54%
Book/sh 0.76
P/B 2.42
EPS next Y -22.54%
ROA -60.26%
Short Interest 0.15M
Perf Year 9.52%
Cash/sh 0.77
P/C 2.40
EPS next 5Y -
ROE -79.69%
52W Range 0.90 - 3.49
Perf YTD -0.54%
Dividend Est. -
P/FCF -
EPS past 5Y -21.09%
ROI -105.37%
52W High -47.28%
Beta 1.54
Dividend TTM -
Quick Ratio 3.37
Sales past 5Y 0.00%
Gross Margin -
52W Low 104.42%
ATR (14) 0.13
Dividend Ex-Date -
Current Ratio 3.37
EPS Y/Y TTM 3.78%
Oper. Margin 0.00%
RSI (14) 43.65
Volatility 5.99% 6.85%
Employees 28
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 6.67
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q -48.01%
Payout -
Rel Volume 0.57
Prev Close 1.84
Sales Surprise -
EPS Surprise 15.62%
Sales Q/Q -
Earnings Mar 26 BMO
Avg Volume 204.47K
Price 1.84
SMA20 -3.97%
SMA50 -6.42%
SMA200 10.33%
Trades
Volume 116,807
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-03-21 Initiated
Oppenheimer
Outperform
$22
Nov-03-21 Initiated
B. Riley Securities
Buy
$27
Apr-02-24 07:30AM
Apr-01-24 07:30AM
Mar-27-24 09:31AM
01:13AM
(Thomson Reuters StreetEvents)
Mar-26-24 11:53AM
07:00AM
Loading…
07:00AM
Mar-15-24 07:30AM
Mar-14-24 04:05PM
Mar-11-24 08:16PM
04:05PM
Mar-06-24 07:30AM
Feb-26-24 07:30AM
Feb-06-24 08:47AM
Jan-04-24 07:30AM
Nov-16-23 07:30AM
07:30AM
Loading…
Nov-15-23 07:30AM
Nov-07-23 07:30AM
Nov-03-23 06:00AM
Nov-02-23 07:30AM
Oct-27-23 07:30AM
Oct-24-23 04:30PM
Oct-16-23 07:30AM
Sep-07-23 07:45AM
Aug-30-23 08:00AM
Aug-09-23 09:09AM
Aug-08-23 09:52PM
(Thomson Reuters StreetEvents)
07:00AM
Aug-02-23 07:30AM
Jul-11-23 07:30AM
Jul-05-23 07:30AM
07:00AM
Loading…
Jun-28-23 07:00AM
Jun-27-23 07:17PM
Jun-20-23 07:30AM
Jun-02-23 07:30AM
May-23-23 09:40AM
07:30AM
May-18-23 03:53PM
07:30AM
May-04-23 04:05PM
May-01-23 07:30AM
Apr-19-23 07:30AM
Apr-12-23 07:30AM
Mar-28-23 07:30AM
Mar-27-23 08:00AM
07:12AM
Mar-23-23 11:03PM
(Thomson Reuters StreetEvents)
07:30AM
Mar-21-23 08:00AM
Mar-16-23 12:18PM
07:30AM
Mar-15-23 07:30AM
Mar-07-23 08:00AM
Feb-22-23 08:00AM
Feb-21-23 07:30AM
Feb-20-23 08:50AM
Feb-09-23 08:00AM
Dec-22-22 08:00AM
Dec-21-22 04:05PM
Dec-15-22 08:00AM
Dec-01-22 08:38AM
(Simply Wall St.) -25.93%
07:30AM
Nov-28-22 08:00AM
Nov-21-22 08:00AM
Nov-15-22 12:55PM
Nov-14-22 08:00AM
Nov-10-22 08:00AM
Oct-12-22 08:00AM
Oct-11-22 08:00AM
Sep-29-22 07:30AM
Sep-27-22 07:32AM
Sep-06-22 07:32AM
Aug-11-22 06:56AM
Aug-09-22 07:00AM
Aug-04-22 04:02PM
02:30PM
Aug-03-22 04:05PM
Jul-19-22 08:00AM
Jun-23-22 07:30AM
Jun-08-22 07:30AM
Jun-02-22 04:01PM
May-13-22 07:30AM
May-11-22 07:00AM
May-04-22 05:54PM
04:01PM
May-03-22 08:00AM
May-02-22 11:18AM
(Simply Wall St.) +13.36%
Apr-25-22 04:01PM
08:00AM
Apr-06-22 07:30AM
Mar-30-22 07:00AM
Mar-22-22 08:00AM
Mar-10-22 07:30AM
Mar-08-22 08:00AM
Feb-08-22 07:30AM
Jan-10-22 07:30AM
Jan-08-22 07:01AM
Jan-04-22 07:30AM
Dec-21-21 07:30AM
Nov-30-21 07:30AM
Nov-18-21 08:00AM
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ricciardi Lisa CEO & President Mar 14 '24 Buy 1.75 5,700 9,975 291,345 Mar 14 04:34 PM
Index -
P/E -
EPS (ttm) -1.47
Insider Own 26.83%
Shs Outstand 10.72M
Perf Week -16.43%
Market Cap 57.35M
Forward P/E -
EPS next Y -1.88
Insider Trans -19.47%
Shs Float 7.86M
Perf Month -39.32%
Income -15.96M
PEG -
EPS next Q -0.43
Inst Own 10.91%
Short Float 5.36%
Perf Quarter 32.18%
Sales 0.00M
P/S -
EPS this Y -38.32%
Inst Trans 0.92%
Short Ratio 1.38
Perf Half Y 58.46%
Book/sh 3.82
P/B 1.40
EPS next Y 7.38%
ROA -31.15%
Short Interest 0.42M
Perf Year 6.80%
Cash/sh 3.85
P/C 1.39
EPS next 5Y -
ROE -32.93%
52W Range 2.38 - 11.99
Perf YTD 24.77%
Dividend Est. -
P/FCF -
EPS past 5Y -39.81%
ROI -38.96%
52W High -55.46%
Beta 1.53
Dividend TTM -
Quick Ratio 16.18
Sales past 5Y 0.00%
Gross Margin -
52W Low 124.37%
ATR (14) 0.94
Dividend Ex-Date -
Current Ratio 16.18
EPS Y/Y TTM -12.02%
Oper. Margin 0.00%
RSI (14) 36.92
Volatility 11.23% 13.13%
Employees 21
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 2.00
Target Price 22.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -24.47%
Payout -
Rel Volume 0.77
Prev Close 5.77
Sales Surprise -
EPS Surprise 2.50%
Sales Q/Q -
Earnings Mar 18 AMC
Avg Volume 305.91K
Price 5.34
SMA20 -33.49%
SMA50 -17.83%
SMA200 14.70%
Trades
Volume 235,319
Change -7.45%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-07-21 Initiated
H.C. Wainwright
Buy
$32
Apr-10-24 08:45AM
Mar-20-24 09:00AM
Mar-19-24 09:06AM
Mar-18-24 08:53PM
05:32PM
04:02PM
Loading…
04:02PM
Mar-15-24 08:00AM
Mar-11-24 07:30AM
Mar-07-24 06:17AM
Mar-05-24 08:01AM
Mar-04-24 08:01AM
Feb-20-24 08:01AM
Feb-15-24 08:01AM
Jan-17-24 07:30AM
Dec-13-23 08:05AM
08:00AM
Loading…
Nov-30-23 08:00AM
Nov-10-23 11:31AM
Nov-08-23 06:43PM
04:01PM
Nov-01-23 08:00AM
Oct-24-23 04:03PM
Oct-10-23 08:00AM
Oct-03-23 08:00AM
Sep-29-23 07:40AM
Sep-25-23 08:30AM
Sep-18-23 09:00AM
Sep-14-23 09:09AM
Aug-31-23 08:00AM
Aug-28-23 05:32PM
08:00AM
06:00PM
Loading…
Aug-23-23 06:00PM
Aug-14-23 08:30AM
Aug-10-23 08:37AM
(Zacks Small Cap Research) +7.07%
Aug-09-23 04:01PM
09:11AM
Aug-08-23 03:06PM
Aug-02-23 12:45PM
08:00AM
Aug-01-23 07:30PM
Jul-30-23 02:45PM
Jul-17-23 08:00AM
Jun-26-23 08:30AM
Jun-12-23 08:30AM
Jun-08-23 09:00AM
May-19-23 06:50AM
May-17-23 08:00AM
May-10-23 09:59AM
(Zacks Small Cap Research)
May-09-23 04:01PM
May-03-23 09:00AM
May-02-23 04:01PM
07:30AM
Apr-13-23 07:30AM
Mar-28-23 08:00AM
Mar-24-23 07:15AM
Mar-22-23 11:50AM
11:45AM
(Zacks Small Cap Research)
Mar-21-23 04:01PM
12:11PM
(Thomson Reuters StreetEvents)
Mar-20-23 04:01PM
Mar-15-23 08:00AM
Mar-13-23 08:00AM
06:16AM
06:00AM
Mar-09-23 08:00AM
Mar-08-23 08:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-27-23 08:00AM
Feb-21-23 12:10PM
Feb-15-23 08:00AM
Feb-01-23 04:55AM
(Zacks Small Cap Research)
Jan-17-23 08:00AM
Jan-05-23 08:59AM
Dec-31-22 06:15AM
Dec-15-22 08:00AM
Dec-13-22 08:00AM
Dec-02-22 01:46PM
08:00AM
Nov-22-22 08:00AM
Nov-08-22 04:48AM
(Zacks Small Cap Research)
Nov-07-22 04:01PM
Nov-02-22 08:00AM
Oct-31-22 08:00AM
Oct-25-22 08:00AM
Oct-21-22 07:00AM
Oct-20-22 07:59AM
Oct-13-22 10:48AM
Oct-11-22 04:00PM
Oct-05-22 08:00AM
Sep-23-22 08:50AM
Sep-19-22 08:50AM
Sep-14-22 12:05PM
08:50AM
Aug-30-22 09:00AM
Aug-19-22 08:30AM
Aug-09-22 08:20AM
(Zacks Small Cap Research)
Aug-08-22 04:01PM
Aug-01-22 07:00AM
Jul-14-22 07:00AM
May-12-22 07:00AM
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kreis Leslie W. 10% Owner Feb 29 '24 Sale 4.87 19,703 95,954 60,256 Feb 29 09:54 PM Fletcher Aaron G.L. 10% Owner Feb 29 '24 Sale 4.87 19,703 95,954 60,256 Feb 29 09:54 PM Fletcher Aaron G.L. 10% Owner Feb 28 '24 Sale 4.85 74,297 360,340 62,088 Feb 29 09:54 PM Kreis Leslie W. 10% Owner Feb 28 '24 Sale 4.85 74,297 360,340 62,088 Feb 29 09:54 PM Kreis Leslie W. 10% Owner Feb 27 '24 Sale 4.40 50,000 220,000 68,997 Feb 29 09:54 PM Fletcher Aaron G.L. 10% Owner Feb 27 '24 Sale 4.40 50,000 220,000 68,997 Feb 29 09:54 PM Kreis Leslie W. 10% Owner Jan 17 '24 Sale 4.20 58,889 247,334 73,646 Jan 19 04:30 PM Fletcher Aaron G.L. 10% Owner Jan 17 '24 Sale 4.20 58,889 247,334 73,646 Jan 19 04:31 PM Kreis Leslie W. 10% Owner Nov 29 '23 Sale 3.44 145,348 499,997 217,553 Dec 01 06:00 AM Fletcher Aaron G.L. 10% Owner Nov 29 '23 Sale 3.44 145,348 499,997 217,553 Dec 01 06:01 AM
Index -
P/E -
EPS (ttm) -1.01
Insider Own 32.38%
Shs Outstand 43.29M
Perf Week -7.21%
Market Cap 44.59M
Forward P/E -
EPS next Y -0.57
Insider Trans 0.00%
Shs Float 29.27M
Perf Month -19.53%
Income -30.01M
PEG -
EPS next Q -0.17
Inst Own 27.31%
Short Float 0.18%
Perf Quarter -23.13%
Sales 0.00M
P/S -
EPS this Y 35.50%
Inst Trans -22.50%
Short Ratio 0.15
Perf Half Y 14.43%
Book/sh 0.58
P/B 1.79
EPS next Y 12.14%
ROA -89.91%
Short Interest 0.05M
Perf Year -10.43%
Cash/sh 0.49
P/C 2.10
EPS next 5Y -
ROE -125.90%
52W Range 0.65 - 3.95
Perf YTD -25.36%
Dividend Est. -
P/FCF -
EPS past 5Y -50.62%
ROI -105.97%
52W High -73.92%
Beta 0.04
Dividend TTM -
Quick Ratio 4.57
Sales past 5Y 0.00%
Gross Margin -
52W Low 58.46%
ATR (14) 0.11
Dividend Ex-Date -
Current Ratio 4.57
EPS Y/Y TTM 25.79%
Oper. Margin 0.00%
RSI (14) 42.16
Volatility 8.46% 9.61%
Employees 31
Debt/Eq 0.20
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 8.62
Option/Short No / Yes
LT Debt/Eq 0.14
EPS Q/Q 33.21%
Payout -
Rel Volume 0.81
Prev Close 1.05
Sales Surprise -
EPS Surprise -43.51%
Sales Q/Q -
Earnings Mar 14 AMC
Avg Volume 343.89K
Price 1.03
SMA20 -8.16%
SMA50 -9.99%
SMA200 -12.72%
Trades
Volume 278,634
Change -1.90%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-18-24 Initiated
Laidlaw
Buy
$7.50
Aug-30-22 Initiated
H.C. Wainwright
Buy
$14
Apr-16-24 04:05PM
Apr-09-24 04:30PM
Mar-14-24 09:54PM
04:00PM
Mar-05-24 04:30PM
08:00AM
Loading…
Feb-26-24 08:00AM
Feb-14-24 08:00AM
Jan-04-24 08:00AM
Dec-11-23 04:05PM
09:00AM
Dec-07-23 08:00AM
Dec-05-23 08:00AM
Nov-20-23 07:00AM
Nov-10-23 07:00AM
Nov-09-23 04:00PM
08:00AM
Loading…
Nov-06-23 08:00AM
Nov-03-23 12:00PM
Nov-02-23 09:17AM
Nov-01-23 08:00AM
Oct-12-23 08:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-20-23 08:00AM
Sep-19-23 08:03AM
Sep-06-23 08:00AM
Aug-15-23 08:00AM
Aug-10-23 04:15PM
Aug-08-23 08:00AM
Jun-05-23 08:00AM
May-17-23 08:00AM
08:00AM
Loading…
May-12-23 08:00AM
May-02-23 05:08PM
May-01-23 08:00AM
Apr-26-23 10:00AM
Apr-25-23 08:00AM
Apr-24-23 08:00AM
Apr-17-23 09:00AM
Apr-11-23 08:00AM
Mar-30-23 04:15PM
Mar-16-23 08:00AM
Mar-01-23 08:00AM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Jan-17-23 07:00AM
Jan-05-23 07:00AM
Jan-03-23 07:00AM
Dec-12-22 07:00AM
Dec-08-22 07:00AM
Nov-10-22 07:30AM
Nov-03-22 09:10AM
Nov-01-22 07:30AM
Sep-27-22 07:30AM
Sep-15-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 07:30AM
Aug-30-22 04:15PM
Aug-19-22 09:20AM
Aug-16-22 04:15PM
Aug-12-22 04:15PM
Aug-11-22 10:05PM
Jul-27-22 07:00AM
Jul-21-22 07:00AM
Jul-12-22 08:00AM
Jul-10-22 09:12AM
Jun-30-22 04:15PM
Jun-08-22 08:00AM
Jun-06-22 07:00AM
May-17-22 07:00AM
May-12-22 08:00AM
May-05-22 08:00AM
May-04-22 08:00AM
May-03-22 11:00AM
(Simply Wall St.) +11.11%
Apr-13-22 08:30AM
Apr-05-22 04:15PM
Mar-28-22 08:00AM
Mar-17-22 04:15PM
Mar-04-22 07:00AM
Feb-10-22 05:36PM
Jan-31-22 12:29PM
(Simply Wall St.) +12.33%
Jan-10-22 07:00AM
Jan-06-22 07:00AM
Dec-16-21 07:00AM
Dec-09-21 04:30PM
Nov-16-21 07:00AM
Nov-11-21 07:00AM
Nov-10-21 04:15PM
Nov-04-21 08:00AM
Nov-01-21 09:28AM
Oct-27-21 07:00AM
Oct-04-21 04:15PM
Sep-10-21 04:15PM
Aug-30-21 07:00AM
Aug-11-21 08:00AM
Aug-04-21 08:00AM
Jul-30-21 07:00AM
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Graff Jeremy R. Director Sep 13 '23 Buy 0.95 2,500 2,375 2,500 Sep 15 04:51 PM McCall Patrick Chief Financial Officer Aug 25 '23 Buy 1.03 1,000 1,030 6,263 Aug 28 04:43 PM Ho William Tai-Wei President and CEO Aug 24 '23 Buy 1.05 23,800 24,990 2,339,545 Aug 28 04:42 PM
Index RUT
P/E -
EPS (ttm) -1.11
Insider Own 3.24%
Shs Outstand 47.22M
Perf Week -10.86%
Market Cap 75.88M
Forward P/E -
EPS next Y -1.00
Insider Trans 0.00%
Shs Float 47.07M
Perf Month -21.21%
Income -50.73M
PEG -
EPS next Q -0.28
Inst Own 32.78%
Short Float 8.93%
Perf Quarter -44.29%
Sales 5.49M
P/S 13.82
EPS this Y 7.03%
Inst Trans -6.78%
Short Ratio 16.31
Perf Half Y -18.32%
Book/sh 0.79
P/B 1.99
EPS next Y 2.71%
ROA -66.40%
Short Interest 4.20M
Perf Year -54.91%
Cash/sh 1.00
P/C 1.56
EPS next 5Y -
ROE -98.73%
52W Range 1.47 - 5.12
Perf YTD -40.91%
Dividend Est. -
P/FCF -
EPS past 5Y 10.55%
ROI -114.14%
52W High -69.53%
Beta 2.02
Dividend TTM -
Quick Ratio 3.01
Sales past 5Y 163.36%
Gross Margin 37.41%
52W Low 6.12%
ATR (14) 0.15
Dividend Ex-Date -
Current Ratio 3.01
EPS Y/Y TTM 25.61%
Oper. Margin -947.01%
RSI (14) 37.58
Volatility 9.41% 8.22%
Employees 53
Debt/Eq 0.40
Sales Y/Y TTM 340.88%
Profit Margin -924.10%
Recom 1.00
Target Price 9.40
Option/Short Yes / Yes
LT Debt/Eq 0.20
EPS Q/Q 23.49%
Payout -
Rel Volume 0.66
Prev Close 1.58
Sales Surprise 88.37%
EPS Surprise 6.67%
Sales Q/Q 1104.15%
Earnings Apr 08 AMC
Avg Volume 257.55K
Price 1.56
SMA20 -13.13%
SMA50 -21.32%
SMA200 -39.97%
Trades
Volume 169,010
Change -1.27%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-13-24 Initiated
Jefferies
Buy
$6
Jun-26-23 Resumed
Oppenheimer
Outperform
$10
Nov-21-22 Initiated
Piper Sandler
Overweight
$7
Jan-13-22 Initiated
H.C. Wainwright
Buy
$20
Jan-03-22 Initiated
Craig Hallum
Buy
$28
Nov-24-20 Initiated
Berenberg
Buy
$30
Apr-09-20 Initiated
Stifel
Buy
$21
Jan-28-20 Initiated
BTIG Research
Buy
$26
Jan-22-20 Initiated
JMP Securities
Mkt Outperform
$22
Apr-15-24 09:55AM
Apr-09-24 07:36AM
(Thomson Reuters StreetEvents) -6.86%
03:02AM
Apr-08-24 04:05PM
Apr-02-24 01:53PM
08:00AM
Loading…
08:00AM
Feb-29-24 10:00AM
Feb-06-24 08:00AM
Dec-14-23 07:04AM
Nov-22-23 08:00AM
Nov-12-23 12:55PM
Nov-09-23 04:05PM
Nov-07-23 08:00AM
Nov-03-23 12:00PM
Nov-02-23 08:00AM
05:39AM
Loading…
Sep-28-23 05:39AM
Sep-27-23 09:05AM
Sep-26-23 08:00AM
Aug-10-23 10:37AM
(Thomson Reuters StreetEvents) -13.26%
10:19AM
08:28AM
Aug-09-23 04:10PM
Aug-02-23 08:00AM
Jun-22-23 06:40AM
Jun-14-23 08:00AM
Jun-07-23 08:00AM
Jun-05-23 08:00AM
May-26-23 06:19AM
May-25-23 05:00PM
May-15-23 08:00AM
05:55PM
Loading…
May-09-23 05:55PM
04:35PM
May-08-23 08:00AM
May-05-23 02:24PM
May-04-23 01:56PM
Apr-25-23 08:00AM
Apr-12-23 08:00AM
Mar-28-23 10:45AM
Mar-24-23 07:28AM
Mar-22-23 07:37AM
(Thomson Reuters StreetEvents)
Mar-21-23 04:10PM
Mar-15-23 08:00AM
Mar-01-23 08:00AM
Feb-22-23 08:00AM
Feb-16-23 10:30AM
08:00AM
Feb-14-23 05:49AM
Feb-01-23 08:00AM
Jan-23-23 08:00AM
Nov-22-22 08:00AM
Nov-17-22 09:00AM
Nov-16-22 05:33AM
Nov-14-22 04:01PM
08:20AM
Nov-10-22 09:00AM
Nov-09-22 08:00AM
Nov-07-22 08:00AM
Oct-17-22 12:18PM
Oct-05-22 08:00AM
Oct-04-22 08:00AM
Sep-07-22 08:00AM
Aug-26-22 06:21AM
Aug-23-22 04:30PM
(Thomson Reuters StreetEvents) +5.57%
09:55AM
Aug-22-22 08:00AM
Aug-04-22 04:30PM
06:35AM
Jul-11-22 08:00AM
Jun-27-22 10:49AM
Jun-13-22 08:00AM
Jun-02-22 06:56AM
Jun-01-22 08:00AM
May-26-22 05:00PM
May-11-22 08:00AM
May-10-22 04:30PM
11:23AM
May-06-22 08:25AM
May-05-22 09:45AM
May-04-22 06:25PM
Apr-05-22 09:09PM
Apr-04-22 09:06AM
Mar-23-22 09:25AM
Mar-19-22 08:19AM
Mar-10-22 08:00AM
Mar-09-22 05:15PM
Mar-02-22 08:00AM
Feb-24-22 05:40PM
Feb-23-22 09:00PM
Feb-15-22 08:22AM
08:00AM
Feb-13-22 06:28PM
08:46AM
Jan-27-22 05:24AM
Jan-26-22 04:01PM
Jan-20-22 08:00AM
Jan-05-22 08:00AM
Dec-30-21 05:49AM
Dec-15-21 08:00AM
Dec-06-21 08:00AM
Nov-22-21 08:00AM
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Suri Anish PRESIDENT AND CSO Aug 25 '23 Buy 2.76 4,000 11,040 135,638 Aug 29 04:08 PM PASSERI DANIEL R CHIEF EXECUTIVE OFFICER Aug 14 '23 Buy 2.86 3,000 8,580 134,578 Aug 16 04:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite